Bionomics Inc.

Ironwood Pharmaceuticals, Inc.

Cyclerion Therapeutics, Inc.

Vasu Sethuraman

Song Xue

Ahmad Hashash

Bernard Luke Flynn

Andrew John Harvey

Dharam Paul

Kwame Wiredu Nti-Addae

Robert C Livingston

Raymond E Forslund

Rob Livingston

David Bruce Hedden

Kristen Marie Leskow

Craig Anthony Dunbar

The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I: Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceutical formulations and dosage forms comprising these solid forms and their uses thereof, alone or in combination with one or more additional agents, for treating and/or preventing various diseases or disorders; these diseases or disorders are ones that may benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).

Solid forms of an sGC stimulator

The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof. 

Salts, co-crystals, and polymorphs of an anxiolytic compound

The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.

Growing community of inventors

Waltham, MA, United States of America

Vasu Sethuraman